gene

LYSOSOME

Entity Detail — Knowledge Graph Node

Understanding Entity Pages

This page aggregates everything SciDEX knows about LYSOSOME: its mechanistic relationships (Knowledge Graph edges), hypotheses targeting it, analyses mentioning it, and supporting scientific papers. The interactive graph below shows its immediate neighbors. All content is AI-synthesized from peer-reviewed literature.

2028Connections

11Hypotheses

0Analyses

50Outgoing

50Incoming

8Experiments

0Debates

Summary

LYSOSOME is a gene implicated in neurodegeneration research. Key relationships include: activates, regulates, associated with. Associated with ALS, Aging, Als. Connected to 1128 entities in the SciDEX knowledge graph.

View on Wiki →

No AI portrait yet

🧬 Gene Info

Gene Symbol	LYSOSOME
Pathways	Akt, Amyloid, Apoptosis, Autophagy, Calcium Signaling
GeneCards	LYSOSOME
Human Protein Atlas	LYSOSOME
Cathepsins	A family of proteases (cathepsins B, D, L) that degrade proteins
Beta-glucocerebrosidase (GBA)	Converts glucosylceramide to glucose and ceramide
Hexosaminidase A	Degrades GM2 gangliosides
Alpha-galactosidase A	Degrades globotriaosylceramide
Lysosomal membrane permeabilization	Leads to release of cathepsins and mitochondrial damage
Macroautophagy	Large protein aggregates are cleared through this pathway
Chaperone-Mediated Autophagy (CMA)	Normal alpha-synuclein is degraded via CMA
Impaired CMA	Mutant A53T alpha-synuclein blocks LAMP-2A, inhibiting its own degradation
Associated Diseases	Aging, Als, Alzheimer, Alzheimer Disease, Amyotrophic Lateral Sclerosis
Interactions	ABCA1, ACTB, Actin, AGING, AIF1, AIM2
KG Connections	2000 knowledge graph edges
Databases	GeneCards UniProt NCBI Gene HPA STRING

Wiki Pages (1)

Knowledge base pages for this entity

Canonical Page

Lysosome Dysfunction in Neurodegeneration

mechanism · 1528 words

→

Pathway Diagram

graph TD
    LYSOSOME["LYSOSOME"] -->|"associated"| NEURON["NEURON"]
    LYSOSOME["LYSOSOME"] -->|"associated"| TAU["TAU"]
    LYSOSOME["LYSOSOME"] -->|"associated"| PRKN["PRKN"]
    LYSOSOME["LYSOSOME"] -->|"associated"| VCP["VCP"]
    LYSOSOME["LYSOSOME"] -->|"interacts"| ALS["ALS"]
    LYSOSOME["LYSOSOME"] -->|"interacts"| Fibrosis["Fibrosis"]
    ATG5["ATG5"] -->|"associated"| LYSOSOME["LYSOSOME"]
    ATG7["ATG7"] -->|"associated"| LYSOSOME["LYSOSOME"]
    APP["APP"] -->|"associated"| LYSOSOME["LYSOSOME"]
    HUNTINGTON["HUNTINGTON"] -->|"associated"| LYSOSOME["LYSOSOME"]
    style LYSOSOME fill:#4a1a6b,stroke:#4fc3f7,stroke-width:2px,color:#e0e0e0

Outgoing (1272)

Target	Relation	Type	Str
Als	inhibits	disease	1.00
SQSTM1	activates	gene	1.00
AUTOPHAGY	regulates	gene	1.00
Cancer	regulates	disease	1.00
Neurodegeneration	activates	disease	1.00
Als	associated_with	disease	1.00
Autophagy	activates	pathway	1.00
Tumor	activates	disease	1.00
AUTOPHAGY	activates	gene	1.00
Autophagy	regulates	pathway	1.00
Als	activates	disease	1.00
Als	therapeutic_target	disease	1.00
Inflammation	activates	disease	1.00
Tumor	therapeutic_target	disease	1.00
Als	regulates	disease	1.00
P62	activates	gene	1.00
UBIQUITIN	activates	gene	1.00
Cancer	therapeutic_target	disease	1.00
Infection	activates	disease	1.00
Autophagy	associated_with	pathway	1.00
AUTOPHAGY	associated_with	gene	1.00
INFLAMMATION	activates	gene	1.00
Autophagy	therapeutic_target	pathway	1.00
Mtor	activates	pathway	1.00
CANCER	regulates	gene	1.00
Autophagy	inhibits	pathway	1.00
GENES	regulates	gene	1.00
UBIQUITIN	regulates	gene	1.00
Proteasome	activates	pathway	1.00
CANCER	therapeutic_target	gene	1.00
Parkinson	therapeutic_target	disease	0.95
Alzheimer	activates	disease	0.95
Neurodegeneration	regulates	disease	0.95
Cancer	activates	disease	0.95
Proteostatic stress	involved_in	process	0.95
Autophagy	regulates	process	0.90
ALZHEIMER	activates	gene	0.90
CANCER	activates	gene	0.90
MITOCHONDRIA	activates	gene	0.90
GENES	activates	gene	0.90
Mitophagy	activates	pathway	0.90
MTOR	activates	gene	0.90
DNA	regulates	gene	0.90
Autophagy	causes	pathway	0.90
DNA	therapeutic_target	gene	0.90
ALZHEIMER'S DISEASE	activates	gene	0.90
PARKINSON	therapeutic_target	gene	0.90
Infection	therapeutic_target	disease	0.85
APP Processing	involved_in	process	0.85
Als	interacts_with	disease	0.85

Incoming (756)

Source	Relation	Type	Str
AUTOPHAGY	associated_with	gene	1.00
AUTOPHAGY	activates	gene	1.00
TRPML1	expressed_in	protein	1.00
AUTOPHAGY	therapeutic_target	gene	1.00
AUTOPHAGY	regulates	pathway	0.94
RUBCN	regulates	entity	0.90
SDC1	translocates_to	entity	0.90
FCRN	protects_against	entity	0.90
MITOCHONDRIAL-DERIVED VESICLES	translocates_to	entity	0.90
Slc45A1	expressed_in	protein	0.90
M6PR	mediates	receptor	0.90
VPS16	participates_in	gene	0.90
GBA1	part_of	gene	0.90
MITOPHAGY	activates	gene	0.90
NEURODEGENERATION	activates	gene	0.90
ROS	activates	gene	0.90
PINK1	regulates	gene	0.90
TREHALOSE	modulates	entity	0.85
GGA3	targets	protein	0.85
LYTAC	targets	compound	0.85
TFEB	regulates	protein	0.84
MTORC1	interacts_with	protein	0.80
CTSD	part_of	gene	0.80
NEURODEGENERATION	therapeutic_target	gene	0.80
TFEB	activates	gene	0.80
MITOPHAGY	regulates	gene	0.80
AUTOPHAGY	inhibits	gene	0.80
MITOPHAGY	associated_with	gene	0.80
ATG	regulates	gene	0.80
LYSOSOMAL BIOGENESIS	activates	gene	0.80
NEURODEGENERATION	regulates	gene	0.80
APOPTOSIS	regulates	gene	0.80
C9ORF72	associated_with	gene	0.75
APOPTOSIS	associated_with	gene	0.70
ATG	activates	gene	0.70
SQSTM1	regulates	protein	0.70
BECN1	activates	gene	0.70
AGING	therapeutic_target	gene	0.70
ATG5	activates	gene	0.70
SQSTM1	activates	gene	0.70
LC3	activates	gene	0.70
ATG	inhibits	gene	0.70
SNAP29	regulates	gene	0.70
AUTOPHAGY	causes	gene	0.70
P62	activates	gene	0.70
PIK3C3	regulates	gene	0.70
PINK1	activates	gene	0.70
PTEN	regulates	gene	0.70
PARKINSON'S DISEASE	therapeutic_target	gene	0.70
NEUROTOXICITY	activates	gene	0.70

Targeting Hypotheses (11)

Hypotheses where this entity is a therapeutic target

Hypothesis	Score	Disease	Analysis
Transcriptional Autophagy-Lysosome Coupling	0.882	neurodegeneration	Autophagy-lysosome pathway convergence a
SGMS1-Driven Sphingomyelin Accumulation Impairs BACE1 Lysoso	0.734	neurodegeneration	What molecular mechanisms link elevated
APOE4-driven lysosome-to-ER cholesterol transport failure re	0.690	molecular biology	Does APOE4's reduced lipid-binding direc
TFEB-Dependent Lysosome Biogenesis	0.690	neurodegeneration	How does controlled lysosomal membrane p
Radiation drives pericyte senescence through lysosome acidif	0.652	neurodegeneration	What specific autophagy pathways are def

Autophagosome-Lysosome Fusion Defects as Primary Driver of α	0.630	neurodegeneration	Gap 006 analysis (archived stub)
Autophagy Activation ULK1/VPS34 (H3): Lipid Routing to Lysos	0.600	neurodegeneration	Does restoring neuronal AMPK activity re
Cytosolic TDP-43 aggregation sequesters SNAP29 and syntaxin-	0.600	neurodegeneration	What are the neuron-specific effects of
HBOT (2.0 ATA, 60 min) activates TFEB-mediated autophagy-lys	0.560	neurodegeneration	What are the optimal oxygen pressure, du
PI3P Generation at Damaged Lysosomes Promotes Membrane Repai	0.530	neurodegeneration	How does controlled lysosomal membrane p
Synaptic-Selective Autophagy Receptor Expression to Bypass A	0.416	proteomics	Quantitative proteomics of the aging syn

Mentioning Analyses (0)

Scientific analyses that reference this entity

No analyses mention this entity

Experiments (8)

Experimental studies targeting or related to this entity

Experiment	Type	Disease	Score	Feasibility	Model	Status	Est. Cost
Autophagy Enhancement Drug Screening for Neurodegeneration	clinical	Alzheimer's Disease	0.400	0.50	human	proposed	$6,550,000
Chaperone-Mediated Autophagy Dysfunction in PD - Experiment Design	clinical	Parkinson's Disease	0.400	0.50	human	proposed	$5,460,000
Macroautophagy Dysfunction in PD - Experiment Design	clinical	Parkinson's Disease	0.400	0.50	human	proposed	$5,460,000
Validate Mitochondria-Lysosome Contact Site Dysfunction in PD	validation	Parkinson's Disease	0.400	0.50	human	proposed	$2,730,000
Mutant Huntingtin (mHTT) Clearance Mechanisms — Therapeutic Target Val	validation	Neurodegeneration	0.400	0.50	human	proposed	$3,000,000
MLCS Quantification in Parkinson's Disease	validation	Parkinson's Disease	0.400	0.50	human	proposed	$2,730,000
Presymptomatic GRN Carrier Intervention Timing — Biomarker-Guided Ther	clinical	Neurodegeneration	0.400	0.50	human	proposed	$5,460,000
TMEM106B Haplotype as Genetic Modifier in FTD — Mechanism and Therapeu	validation	Neurodegeneration	0.400	0.50	human	proposed	$2,730,000

Related Papers (20)

Scientific publications cited in analyses involving this entity

Title & PMID	Authors	Journal	Year	Citations
Hepatocyte FoxO1 Deficiency Protects From Liver Fibrosis via Reducing Inflammati [PMID:37678798]	Pan Q, Gao M, Kim D, Ai W, Yang W, Jiang	Cell Mol Gastroenterol Hepatol	2024	1
Metabolic orchestration of cell death by AMPK-mediated phosphorylation of RIPK1. [PMID:37384704]	Zhang T, Xu D, Trefts E, Lv M, Inuzuka H	Science	2023	1
Cinobufagin induces FOXO1-regulated apoptosis, proliferation, migration, and inv [PMID:35176466]	Zhang L, Liang B, Xu H, Gong Y, Hu W, Ji	J Ethnopharmacol	2022	1
Metformin Improves Mitochondrial Respiratory Activity through Activation of AMPK [PMID:31693892]	Wang Y, An H, Liu T, Qin C, Sesaki H, Gu	Cell Rep	2019	1
AMPK-Mediated BECN1 Phosphorylation Promotes Ferroptosis by Directly Blocking Sy [PMID:30057310]	Song X, Zhu S, Chen P, Hou W, Wen Q, Liu	Curr Biol	2018	1
Obestatin controls the ubiquitin-proteasome and autophagy-lysosome systems in gl [PMID:28675664]	Cid-Díaz T, Santos-Zas I, González-Sánch	J Cachexia Sarcopenia Muscle	2017	1
PTEN loss drives B7H3 upregulation via the mTORC2/FOXO/c-Myc axis to promote tum [PMID:41920736]	Wang Z, Jin N, Li X, Ma X, Feng Y, Yin K	Cell reports	2026	0
Mammalian lipophagy: process and function. [PMID:41681129]	Zhao R, Dai E, Kang R, Liu J, Klionsky D	Autophagy	2026	0
TAZ alleviates ischemic stroke injury by activating Foxo1: Usp1-mediated deubiqu [PMID:41921828]	["Xin Y", "Sun Y", "Pan E", "Li M", "Che	Free radical biology & medicin	2026	0
Combining network pharmacology and multi-omics reveals the role of Shengdihuang- [PMID:41655545]	Cao X, Shang Y, Qu M, Kang Q, Xu Y et al	Phytomedicine	2026	0
Comparative transcriptomics of adherent and suspension chicken fibroblast cell l [PMID:41763754]	Contreras EJ, Nagarajan A, Bromberg BH,	Food Res Int	2026	0
FOXO1 transcription factor modulates airway epithelial responses to viral infect [PMID:41931532]	Daniel NM, Mann-Nüttel R, Shrestha Palik	PLoS One	2026	0
Effects of Vitamin A Restriction on Carcass Characteristics, Antioxidant Capacit [PMID:41856090]	Zhang X, Zhang C, Song J, Bai J, Hao B,	Animal bioscience	2026	0
Transcriptomic identification of CREB1 and FOXO1 activation in neuregulin-1-medi [PMID:41907189]	Bennett KR, Surles-Zeigler MC, Augello C	Frontiers in molecular neurosc	2026	0
Human MKP-3 isoforms display differential structural and functional profiles. [PMID:41865406]	Mori Sequeiros Garcia MM, Nudler S, Bigi	Biochemical and biophysical re	2026	0
Role of Uncertainty in Illness and Coping Strategies in Advance Directive Comple [PMID:38567890]	["Fuson O", "Mitra A", "Little C", "Hiat	Journal of clinical gastroente	2025	0
The GLP-1 agonist semaglutide ameliorates cognitive regression in P301S tauopath [PMID:39875022]	["Elbadawy N", "Saad M", "Elfarrash S",	European journal of pharmacolo	2025	0
The cholesterol 24-hydroxylase CYP46A1 promotes α-synuclein pathology in Parkins [PMID:39964974]	Dai L, Wang J, Meng L, Zhang X, Xiao T,	PLoS biology	2025	0
The multifaceted impact of physical exercise on FoxO signaling pathways. [PMID:40861274]	Liu W, Meng P, Li Z, Shen Y, Meng X, Jin	Frontiers in cell and developm	2025	0
Programmable protein stabilization with language model-derived peptide guides. [PMID:40229275]	["Hong L", "Ye T", "Wang T", "Srijay D",	Nature communications	2025	0

Debates (0)

Multi-agent debates referencing this entity

No debates reference this entity

Related Research

Hypotheses and analyses mentioning LYSOSOME in their description or question text